CDRH Can’t Rely On ‘Network of Experts’ Due To Confidentiality Concerns
This article was originally published in The Gray Sheet
CDRH Director Jeff Shuren told a Senate panel April 28 that an obstacle to getting outside expertise on innovative devices to gain the know-how to appropriately review them is companies’ confidentiality concerns, and inability of firms to share access to their proprietary data.
You may also be interested in...
An FDA Science Board subcommittee report finds industry and researcher perceptions of FDA's science readiness has improved over the past eight years. But the agency still faces major challenges tied to the current speed of scientific and technical progress.
But the April 29 updated draft of the broad-based House reform package for medical innovation is missing some significant items floated earlier this year, including a Medicare breakthrough device program, a revamp of diagnostics regulations and device supply-chain security reform.
A significant new addition to the legislative proposal would double the number of people that could be treated per year with a humanitarian device exemption product from 4,000 to 8,000.
The device center has committed to metrics for draft guidance documents, trying to address complaints that policies linger too long in the draft stage and create regulatory confusion. CDRH also highlighted recent website upgrades intended to better distinguish between draft and final guidance documents.